| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $504K | -18.4% | -79.0% |
| SG&A Expense | $1.3M | +8.8% | +52.4% |
| Operating Income | -$1.8M | +0.7% | +45.4% |
| Net Income | -$1.7M | +0.5% | +46.7% |
| EPS (Basic) | -$1.65 | +0.6% | +91.9% |
| EPS (Diluted) | -$1.65 | +0.6% | +91.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.7M | -28.0% | — |
| Total Assets | $5.1M | -23.6% | -24.2% |
| Total Liabilities | $1.1M | +8.3% | -42.9% |
| Stockholders' Equity | $4.0M | -29.5% | -16.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.4M | — | — |
| Financing Cash Flow | $7.9M | — | — |